COMPASS Pathways 2026 Stifel Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Great. Thanks very much. Super happy to be moderating this chat with the COMPASS Pathways team. With me is Steve Levine, Chief Patient Officer, and Lori Englebert, Chief Commercial Officer. COMPASS just got the NDA submission in, so congratulations on that. Happy to kick it over to whoever wants to start, but I think the most interesting conversation here really just sort of centers around what you're doing right now with launch prep and stuff like that. So, feel free to take it away.
You want to start? Yeah, I'll start and, of course, make the obligatory statement that we may make forward-looking statements, so please refer to the investor page of our website.
Can I just, since we know each other so well. I saw a really funny thing online today that said, "Biotech companies lead off by saying, 'We're making forward-looking statements,' and AI companies lead off by saying, 'We are curing cancer, all cancer in the next 10 years.'" I was like, "That is awesome.
Nonetheless- Do you want us to jump in?
This is for SEC filing.
Sure, that's fine. But anyways, it just reminded me of it.
We're going to cure cancer.
We're lawyered up much more than the AI companies are, right?
Yeah. Apparently, yeah. That's all.
With that, go ahead. Yeah.
First, for those that aren't familiar with COMPASS Pathways, we are a biotechnology company that has been developing a synthetic proprietary formulation of psilocybin that we call COMP360. Earlier this week, we announced that we have completed the submission of our NDA, which we had already been submitting on a rolling basis and has been reviewed on a rolling basis, for our lead indication in treatment-resistant depression. This represents two large phase III studies and supported by a large phase II, in which we have demonstrated a generally safe and well-tolerated profile with a very highly differentiated set of efficacy outcomes with very rapid onset of effect, detected as of the first measured time point, 24 hours after the first administration.
And with data now out to up to 52 weeks, demonstrating that with just up to a few administrations in a year, there may be durable efficacy with a frequency of treatment that we've never seen before. We are very excited for the ongoing review of this application under our national priority review voucher. This potentially is a contracted review period, and with that, we've been very busy preparing for commercialization, which I will hand over to Lori.
Yeah, you want me to just keep rolling?
Please. Before we keep going, I just want to say, if Steve and I act like we share a brain, we do.
Because we do. He is a real psychiatrist.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
